Core Insights - Journey Medical Corporation will be included in the Russell 2000 and Russell 3000 Indexes effective after the close of U.S. equity markets on June 27, 2025, due to the 2025 annual Russell Index reconstitution [1][2] - The inclusion in these indexes is expected to enhance the company's visibility among investors and institutions [2] - Journey Medical's FDA-approved product, Emrosi™, for treating inflammatory lesions of rosacea, is experiencing a strong market entry, with plans to expand access and grow prescription volume [2] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [6][7] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [6] - Founded by Fortress Biotech, Inc., Journey Medical is based in Scottsdale, Arizona [7] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, which are widely utilized by investment managers and institutional investors [2]

National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatmen ...

Core Insights - AAR CORP.'s subsidiary Trax has been selected to modernize Delta TechOps' maintenance and engineering systems, indicating a significant partnership in aviation maintenance technology [1][2] - The modernization will involve replacing legacy systems with Trax's eMRO and eMobility solutions, enhancing efficiency and operational performance for over 6,000 technicians [2][4] - AAR's strategic investments in Trax have positioned the company to support large airlines and diverse fleets, showcasing its growth and capability in the aviation sector [3][4] Company Overview - AAR CORP. is a global aerospace and defense aftermarket solutions provider, operating in over 20 countries and supporting both commercial and government customers through various segments [4] - Trax, as a wholly-owned subsidiary of AAR, specializes in aviation maintenance mobile and cloud products, offering comprehensive software solutions for aircraft maintenance [5] - Delta TechOps, the maintenance division of Delta Air Lines, provides extensive maintenance, repair, and overhaul services, emphasizing safety, quality, and innovation in aviation maintenance [6]

Core Insights - Fortress Biotech, Inc. has initiated the commercial launch of Emrosi™ for treating inflammatory lesions of rosacea in adults, following FDA approval in November 2024 [4] - The company reported a net loss of $(12.7) million, or $(0.48) per share, for Q1 2025, an improvement from a net loss of $(17.9) million, or $(1.04) per share, in Q1 2024 [12][18] - Fortress' subsidiary Checkpoint Therapeutics is set to be acquired by Sun Pharma, with expected upfront cash payment of approximately $28 million and potential future royalties [3][2] Financial Results - Fortress' consolidated cash and cash equivalents increased to $91.3 million as of March 31, 2025, up from $57.3 million at the end of 2024, marking a $34 million increase [12][14] - Consolidated net product revenue for Q1 2025 was $13.1 million, slightly up from $13.0 million in Q1 2024 [9][18] - Research and development expenses for Q1 2025 totaled $3.9 million, a significant decrease from $24.8 million in Q1 2024 [12][18] Regulatory Updates - The FDA accepted the New Drug Application for CUTX-101 for Menkes disease, with a PDUFA goal date of September 30, 2025 [2][8] - UNLOXCYT, an anti-PD-L1 antibody developed by Checkpoint, was approved by the FDA in December 2024 for treating patients with metastatic or locally advanced cutaneous squamous cell carcinoma [8] Commercial Product Updates - Emrosi was launched by Journey Medical Corporation, with initial prescriptions filled at the end of March 2025 [4][18] - Full results from two Phase 3 clinical trials evaluating Emrosi were published, demonstrating its efficacy and safety for treating moderate-to-severe papulopustular rosacea [18] Corporate Highlights - Fortress has a robust pipeline with multiple late-stage programs and newly approved products, positioning the company for continued revenue growth [2] - The acquisition of Checkpoint by Sun Pharma is expected to enhance patient access to Checkpoint's products and create significant monetization opportunities for Fortress [3][2]

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ( ...

Core Insights - The global aerospace services sector is experiencing significant growth, driven by rising air traffic, increased aircraft utilization, and a booming Maintenance, Repair, and Overhaul (MRO) market, benefiting companies like AerSale Corporation (ASLE) and AAR Corp. (AIR) [1][2] Summary of AerSale (ASLE) - Recent achievements include strategic investments, such as the opening of a new MRO facility in Millington, TN, and the expansion of operations in Miami, which are expected to significantly contribute to future revenues [3] - In January 2025, AerSale acquired a parts portfolio from the Sanad Group, enhancing its inventory with high-demand components for popular aircraft models, thereby expanding its customer base [4] - Financial stability is highlighted by cash and cash equivalents of $12 million and low debt levels, indicating a strong solvency position that allows for investment in new products and shareholder returns [5][6] - Challenges include reliance on feedstock availability for Used Serviceable Material (USM) sales, which could constrain revenue and margins, and potential slow commercial adoption of innovations like AerAware [7] Summary of AAR Corp. (AIR) - Recent achievements include record MRO spending benefiting AIR, with notable contracts such as Amerijet International Airlines selecting AIR's subsidiary Trax for maintenance operations [8][9] - Financial stability is characterized by cash and cash equivalents of $101 million, but long-term debt of $1,022 million raises concerns about cash flow and investment capacity [10] - Challenges include ongoing supply-chain issues that may lead to production delays and sluggish cash flow, impacting the company's ability to meet growing demand [12] Comparative Analysis - Zacks Consensus Estimates indicate that AerSale's 2025 sales and earnings per share (EPS) are expected to improve by 6.8% and 288.9%, respectively, while AIR's sales are projected to grow by 17.2% and EPS by 12.6% [13][14] - Stock price performance shows ASLE has outperformed AIR over the past three months and year, with ASLE down 4.8% compared to AIR's 23.6% decline [15] - Valuation metrics reveal AerSale's forward earnings multiple at 8.98X is more attractive than AIR's 11.94X, suggesting a better investment opportunity [16] Conclusion - AerSale is positioned as the more compelling investment choice for 2025 due to its attractive valuation, consistent outperformance, and diversified business model, while AIR faces challenges from supply-chain issues and declining earnings estimates [19][20]